328236-44-8Relevant academic research and scientific papers
Preparation method of cyclic phosphonate compound
-
Paragraph 0026-0028; 0031-0032, (2021/09/04)
The invention provides a preparation method of a cyclic phosphonate compound. The preparation method comprises the following steps: (1) reacting a compound as shown in a formula 9 with a chlorination reagent to obtain a phosphonyl chloride intermediate 11
PREPARATION METHOD OF A CYCLIC PHOSPHONATE COMPOUND
-
Paragraph 0049; 0052; 0053, (2021/09/10)
A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.
Chasing the Elusive Benzofuran Impurity of the THR Antagonist NH-3: Synthesis, Isotope Labeling, and Biological Activity
Singh, Latika,Pressly, Brandon,Mengeling, Brenda J.,Fettinger, James C.,Furlow, J. David,Lein, Pamela J.,Wulff, Heike,Singh, Vikrant
, p. 1870 - 1876 (2016/03/15)
We have synthesized and established the structure of a long-suspected, but hitherto unknown, benzofuran side product (EBI) formed during the synthesis of NH-3. Understanding the mechanism of its formation has enabled isotope (D) labeling. We further devel
Novel Phosphinic Acid-Containing Thyromimetics
-
Page/Page column 108, (2009/02/11)
The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.
NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS
-
Page/Page column 248, (2008/06/13)
The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.
Improved synthesis of the iodine-free thyromimetic GC-1
Chiellini, Grazia,Nguyen, Ngoc-Ha,Yoshihara, Hikari A.I.,Scanlan, Thomas S.
, p. 2607 - 2611 (2007/10/03)
Synthesis of the TRβ-selective thyromimetic GC-1 has been improved using methoxymethyl (MOM) and triisopropylsilyl (TiPS) substituents as phenolic protecting groups. The new synthetic route is adaptable to analogue design. (C) 2000 Elsevier Science Ltd.
